AstraZeneca Plc and Daiichi Sankyo Co Ltd signed a deal to develop and sell Daiichi's cancer drug trastuzumab deruxtecan that could see the British drugmaker pay as much as $6.9 billion to its Japanese partner.
More From BioPortfolio on "AstraZeneca in cancer drug deal that could pay Daiichi Sankyo up to $6.9 billion"